Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders: A symptom-based, patient-level analysis of randomized, placebo-controlled trials.

MLA

Dold, Markus, et al. “Baseline Symptom Severity and Efficacy of Silexan in Patients with Anxiety Disorders: A Symptom-Based, Patient-Level Analysis of Randomized, Placebo-Controlled Trials.” European Psychiatry : The Journal of the Association of European Psychiatrists, vol. 67, no. 1, Mar. 2024, p. e23. EBSCOhost, https://doi.org/10.1192/j.eurpsy.2024.16.

APA

Dold, M., Möller, H.-J., Volz, H.-P., Seifritz, E., Schläfke, S., Bartova, L., & Kasper, S. (2024). Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders: A symptom-based, patient-level analysis of randomized, placebo-controlled trials. European Psychiatry : The Journal of the Association of European Psychiatrists, 67(1), e23. https://doi.org/10.1192/j.eurpsy.2024.16

Chicago

Dold, Markus, Hans-Jürgen Möller, Hans-Peter Volz, Erich Seifritz, Sandra Schläfke, Lucie Bartova, and Siegfried Kasper. 2024. “Baseline Symptom Severity and Efficacy of Silexan in Patients with Anxiety Disorders: A Symptom-Based, Patient-Level Analysis of Randomized, Placebo-Controlled Trials.” European Psychiatry : The Journal of the Association of European Psychiatrists 67 (1): e23. doi:10.1192/j.eurpsy.2024.16.